Aktie A2QMUF IR-MED INC.
Zu einer Liste hinzufügen
Um diese Funktionalität nutzen zu können, müssen Sie Mitglied sein
EinloggenRegistrieren

Andere Sprachen IR-Med Inc.

Aktien

A2QMUF

US46265R1032

IRME

Markt geschlossen - OTC Markets
Andere Börsenplätze
 21:49:55 16.05.2024 		% 5 Tage % 1. Jan.
0,6412 USD -24,56 % Intraday Chart für IR-Med Inc. -28,74 % -44,23 %
05.04. PressureSafe von IR-Med Inc. erhält FDA-Listung für die Indikation der Entscheidungshilfe bei Druckverletzungen CI
01.04. IR-Med Inc. meldet Ergebnis für das am 31. Dezember 2023 endende Geschäftsjahr CI

Andere Sprachen

Suchen
Ergebnisse ansehen
Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!
100% kostenlose Registrierung
IR-Med Inc.'S PressureSafe Receives FDA Listing for the Indication of Decision Support Device for Pressure Injuries
IR-MED’s PressureSafe™ Receives FDA Listing for the Indication of Decision Support Device for Pressure Injuries
IR-Med Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
IR-Med Inc. and I.R Med Ltd. Appoints Aharon Klein as Interim Chief Executive Officer
IR-Med Inc. Announces Cessation of Tzur Di-Cori Pursuant as Chief Executive Officer
IR-Med Inc. Announces Resignation of Inna Martin as Director
IR-MED Reports 92% Efficacy for PressureSafe™ in Early, Non-Invasive, Skin Color Agnostic Detection of Pressure Injuries
IR-MED to Report New Clinical Efficacy Data for Detection of Pressure Injuries with its AI- Based PressureSafe™ Device at NPIAP 2024 Annual Conference on February 16
IR-MED to Report New Clinical Efficacy Data for Detection of Pressure Injuries with its AI- Based PressureSafe? Device at NPIAP 2024 Annual Conference on February 16
IR-MED Awarded Most Innovative Non-Invasive Diagnostics Technology Developer 2023 by Corporate Vision Magazine
IR-MED Granted Patent in Israel for its AI-Driven Platform Technology: Non-Invasive Analysis of Subcutaneous Tissue
IR-Med Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
IR-MED Appoints Healthcare Executive and Entrepreneur Tzur Di-Cori as Chief Executive Officer
IR-MED Announces Executive Changes Effective as of October 15, 2023
IR-MED to Conduct Usability Study with Methodist Healthcare of San Antonio for its PressureSafe Device Which is Slated for U.S. Launch in H1 2024
Ir-Med to Conduct Usability Study with Methodist Healthcare of San Antonio for Its Pressuresafe Device Which Is Slated for U.S. Launch in H1 2024
IR-MED Appoints Richard Serbin, Esq. to its Advisory Board
IR-Med Inc. Appoints Richard Serbin, Esq. to Its Advisory Board
IR-MED Chairman & Interim CEO Issues Letter to Shareholders
IR-Med Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
Keine Ergebnisse zu dieser Suche
Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Filter

Suchen

Datum der Veröffentlichung

Vom

Bis

  1. Börse
  2. Aktien
  3. A2QMUF Aktie
  4. Nachrichten IR-Med Inc.
  5. Andere Sprachen